BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29752546)

  • 1. MiR-514 attenuates proliferation and increases chemoresistance by targeting ATP binding cassette subfamily in ovarian cancer.
    Xiao S; Zhang M; Liu C; Wang D
    Mol Genet Genomics; 2018 Oct; 293(5):1159-1167. PubMed ID: 29752546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.
    Lv T; Song K; Zhang L; Li W; Chen Y; Diao Y; Yao Q; Liu P
    Biochem Cell Biol; 2018 Oct; 96(5):663-671. PubMed ID: 29561664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
    Wu D; Lu P; Mi X; Miao J
    Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    Li N; Yang L; Wang H; Yi T; Jia X; Chen C; Xu P
    PLoS One; 2015; 10(6):e0128886. PubMed ID: 26043084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STAT3 regulated
    Jin P; Liu Y; Wang R
    Biosci Rep; 2018 Aug; 38(4):. PubMed ID: 30061175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
    Niu Q; Liu Z; Gao J; Wang Q
    Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long Noncoding RNA LINC01125 Enhances Cisplatin Sensitivity of Ovarian Cancer via miR-1972.
    Guo J; Pan H
    Med Sci Monit; 2019 Dec; 25():9844-9854. PubMed ID: 31865363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
    Xiao F; Li Y; Wan Y; Xue M
    Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
    Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of miR-128 in ovarian cancer promotes cisplatin resistance.
    Li B; Chen H; Wu N; Zhang WJ; Shang LX
    Int J Gynecol Cancer; 2014 Oct; 24(8):1381-8. PubMed ID: 25248111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-770-5p inhibits cisplatin chemoresistance in human ovarian cancer by targeting ERCC2.
    Zhao H; Yu X; Ding Y; Zhao J; Wang G; Wu X; Jiang J; Peng C; Guo GZ; Cui S
    Oncotarget; 2016 Aug; 7(33):53254-53268. PubMed ID: 27449101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Over-expression of miR-31 or loss of KCNMA1 leads to increased cisplatin resistance in ovarian cancer cells.
    Samuel P; Pink RC; Caley DP; Currie JM; Brooks SA; Carter DR
    Tumour Biol; 2016 Feb; 37(2):2565-73. PubMed ID: 26386726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
    Zhang X; Huang L; Zhao Y; Tan W
    Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-378a-3p sensitizes ovarian cancer cells to cisplatin through targeting MAPK1/GRB2.
    Xu ZH; Yao TZ; Liu W
    Biomed Pharmacother; 2018 Nov; 107():1410-1417. PubMed ID: 30257357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
    Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
    Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-194-5p inhibits SLC40A1 expression to induce cisplatin resistance in ovarian cancer.
    Wu J; Zhang L; Wu S; Yi X; Liu Z
    Pathol Res Pract; 2020 Jul; 216(7):152979. PubMed ID: 32534701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
    Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
    Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
    Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
    Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.